📰 Thomasf Gajewski News
Thomasf Gajewski News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Thomasf Gajewski. Real-time updates on events, politics, business and more.
May 23, 2024
Thomas F. Gajewski, MD, PhD, discusses the mechanism through which the gut microbiome modulates myeloid cells to regulate responses to immunotherapy.
June 6, 2023
Jounce Therapeutics (NASDAQ:JNCE – Get Rating) and Kymera Therapeutics (NASDAQ:KYMR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations. Institutional & Insider Ownership 80.7% of Jounce Therapeutics shares […]
June 5, 2023
StockNews.com initiated coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report sent to investors on Thursday. The firm issued a hold rating on the stock. Several other analysts have also commented on the stock. Piper Sandler lowered shares of Jounce Therapeutics from an overweight rating to a neutral rating in […]
June 3, 2023
Investment analysts at StockNews.com started coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the stock. Other analysts have also recently issued research reports about the stock. Raymond James cut shares of Jounce Therapeutics from an “outperform” rating to a “market […]
May 28, 2023
StockNews.com assumed coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the stock. A number of other analysts have also issued reports on JNCE. Sumitomo Mitsui Financial Group reissued a neutral rating on shares of Jounce Therapeutics in […]
May 12, 2023
StockNews.com started coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a report issued on Monday morning. The brokerage issued a hold rating on the stock. A number of other research analysts have also recently commented on JNCE. Piper Sandler cut shares of Jounce Therapeutics from an overweight rating to a neutral rating […]
May 11, 2023
StockNews.com assumed coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report released on Monday morning. The brokerage issued a hold rating on the stock. Several other research firms have also issued reports on JNCE. Sumitomo Mitsui Financial Group reissued a neutral rating on shares of Jounce Therapeutics in a report […]
May 8, 2023
Stock analysts at StockNews.com assumed coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock. JNCE has been the subject of several other reports. Piper Sandler cut Jounce Therapeutics from an “overweight” rating to a […]
May 3, 2023
Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 2,020,000 shares, a drop of 11.4% from the March 31st total of 2,280,000 shares. Based on an average trading volume of 2,640,000 shares, the days-to-cover ratio is […]
May 3, 2023
StockNews.com started coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the stock. A number of other analysts have also weighed in on the stock. Sumitomo Mitsui Financial Group restated a neutral rating on shares of Jounce […]